PharmaClik Login 
Pharmacists are highly trained healthcare professionals who play a vital role in the management of patients' health, including the prescribing of medications. Pharmacist prescribing authority – their ability to prescribe medications, initiate and adjust doses, and manage drug therapeutic substitutions for patients without the need for physician involvement – has been an ongoing topic of policy discussions across all Canadian provinces in the aftermath of the COVID-19 pandemic. Expanding prescribing authority to pharmacists’ full capabilities across all provinces has never been more urgent and relevant than in this period of severe, enduring healthcare professional shortage across the country.
McKesson Canada Expands Patient Access to Cutting-Edge Radioligand Therapy in Ontario - McKesson Canada
Press Releases
Stay Informed with Our Latest Healthcare Updates and Announcements
Press Releases
Stay Informed with Our Latest Healthcare Updates and Announcements
Mississauga, Ontario (March 24, 2025) – McKesson Canada is pleased to announce it has started treating patients with radioligand therapy (RLT) at its newest INVIVA infusion clinic in Toronto, the first time this groundbreaking treatment has been available to patients outside of a hospital setting in Ontario.
"By offering radioligand therapy at INVIVA, we are expanding access to this transformative treatment for patients across the province, while also reinforcing our commitment to advancing patient care," says Dimitris Polygenis, President, Specialty Health, McKesson Canada.
Radioligand therapy represents a breakthrough in nuclear medicine, offering a targeted approach that can significantly improve outcomes for patients with various forms of cancer. By delivering radiation directly to cancer cells, RLT minimizes impact on healthy tissue, resulting in a more precise and effective treatment.
The organization has invested extensively in the infrastructure and certification needed to deliver nuclear medicine safely and effectively. Staff have undertaken comprehensive training, and the clinic has been licensed by the Canadian Nuclear Safety Commission (CNSC), which requires adherence to rigorous quality assurance standards.
“While only a few RLT drugs are currently available in Canada – primarily to treat certain forms of cancer, such as prostate and neuroendocrine tumours – we know this is a rapidly evolving area of medicine,” says Lee Steele, Vice President, INVIVA & Chief Nursing Officer, McKesson Canada. “We felt it was important to invest in building a clinic that was capable of delivering these cutting-edge treatments in order to improve health outcomes for patients in Ontario.”
For more information about RLT at INVIVA’s newest clinic, visit inviva.ca/radioligand-therapy.
About INVIVA
Established in 2013, today INVIVA is Canada's largest private infusion network with 68 clinics that provide patients with specialized therapy in a caring and compassionate setting. INVIVA experts work directly with manufacturers to bring specialty therapies and nursing services to patients in need while improving access. They engage with health care providers to improve the patient experience and make it easier for everyone to manage complex diseases. Its team of highly trained seasoned nurses help manage various therapeutic areas, including gastroenterology, rheumatology, geriatrics, pediatrics, and more. In 2023, INVIVA was awarded accreditations in Cancer Care, Ambulatory Care, Home Care Services, Leadership, Infection Prevention and Control, and Medication Management making it the first national private infusion network with accreditation.
About McKesson Canada
McKesson Canada is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with pharmaceutical companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson Canada is impacting virtually every aspect of healthcare at www.McKesson.ca.
Media contact:
Sybil Millar
Senior Advisor, Media Relations and External Communications, McKesson Canada
media@mckesson.ca
A significant public policy priority for the Government of Canada is ensuring comprehensive, timely, and equitable access to medication for rare diseases; as such, the Government of Canada has allocated $500 million annually to a national strategy for rare disease drugs. McKesson Canada is proud to contribute to this conversation, drawing on experience with patient support programs, pharmaceutical distribution, and specialty pharmacy services.
The Government of Canada would like to develop a solution to ensure universal drug coverage for Canadians. This solution would mean all Canadians would have access to a comprehensive, affordable drug insurance plan regardless of their province of residence or financial situation. Where the coverage comes from is an important consideration, but what ultimately matters is that all Canadians can acquire the medicine they need regardless of their particular financial, geographic or health circumstances.
